Physician profile
Patrick J Hogan
NPI 1245237734
$116,499.86
in general payments reported to CMS, 2019-2025
39 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $22K · 2021: $25K · 2022: $14K · 2023: $2,792 · 2024: $1,527 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,309 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,225 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,225.00 |
| Education | $313.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35,552.62 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $25,773.28 | 2019-2020 | |
| Abbvie INC. | $20,045.24 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $15,636.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $10,856.24 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $4,652.20 | 2019-2025 | Dysport |
| Merz Pharmaceuticals, LLC | $589.25 | 2021-2025 | Xeomin |
| Upsher-Smith Laboratories LLC | $389.97 | 2019-2023 | |
| Pfizer INC. | $362.70 | 2023-2025 | |
| Lilly USA, LLC | $254.15 | 2019-2024 | Emgality, Reyvow |
| Acadia Pharmaceuticals INC | $237.26 | 2019-2023 | Nuplazid |
| Amneal Pharmaceuticals LLC | $211.06 | 2019-2025 | Rytary, Brekiya |
| Acorda Therapeutics, INC | $192.10 | 2019-2024 | Inbrija |
| Lundbeck LLC | $162.81 | 2019-2025 | Vyepti |
| Amgen INC. | $158.58 | 2019-2022 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.